Overview

Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy

Status:
Unknown status
Trial end date:
2010-03-01
Target enrollment:
0
Participant gender:
All
Summary
Retrospective longitudinal cohort study with 36 HIV naïve-treatment patients, who started therapy with lopinavir/ritonavir or efavirenz (LPV/r or EFZ), follow-up of 36 months. Primary endpoint: virological success (HIV RNA <50 copies/mL) in the first six months and at the end of the study.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
UPECLIN HC FM Botucatu Unesp
Treatments:
Anti-Retroviral Agents
Efavirenz
Lopinavir
Ritonavir
Criteria
Inclusion Criteria:

- HIV-1 infected naive-treatment patients

Exclusion Criteria:

- use of Anti-Retroviral Agents in the past